GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.86 Average Price Target from Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.86.

GDRX has been the topic of several recent analyst reports. Raymond James upgraded GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 price objective on the stock in a research note on Friday, August 9th. Citigroup cut their price target on shares of GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. UBS Group reduced their target price on GoodRx from $9.00 to $8.50 and set a "neutral" rating for the company in a report on Friday, August 9th. Finally, Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Monday, November 11th.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.17% of the stock is owned by company insiders.

Hedge Funds Weigh In On GoodRx

Large investors have recently modified their holdings of the company. Beacon Capital Management LLC purchased a new stake in GoodRx in the 1st quarter worth approximately $28,000. nVerses Capital LLC bought a new position in shares of GoodRx in the third quarter worth $33,000. Plato Investment Management Ltd bought a new position in shares of GoodRx in the second quarter worth $43,000. EP Wealth Advisors LLC purchased a new stake in shares of GoodRx in the third quarter worth $73,000. Finally, Sanctuary Advisors LLC bought a new stake in GoodRx during the third quarter valued at $85,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Stock Up 2.1 %

NASDAQ GDRX traded up $0.10 during trading hours on Wednesday, hitting $4.86. The company's stock had a trading volume of 682,304 shares, compared to its average volume of 1,448,736. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company's 50-day simple moving average is $6.11 and its two-hundred day simple moving average is $7.29. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.